Ravulizumab
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Ravulizumab. It is indicated for AchR antibody positive myasthenia gravis. Fully referenced neurology checklist.
Pharmacology
- It is indicated for AchR antibody positive myasthenia gravis
- It is usually indicated in refractory cases
- This is usually in patients resistant to Eculizumab
Dosing
Locked: subscribe to see this section.
Administration
Locked: subscribe to see this section.
Frequent adverse events
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
Benefits
Locked: subscribe to see this section.
Non-MG indications
Locked: subscribe to see this section.
References
- Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther 2023; 12:25-45.
- Sánchez-Tejerina D, Sotoca J, Llaurado A, López-Diego V, Juntas-Morales R, Salvado M. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med 2022; 11:6394.Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther 2023; 23:235-241.
- Meisel A, Annane D, Vu T, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 2023; 270:3862-3875.
